A recently published study from the Dana-Farber Cancer Institute has determined that patients with multiple myeloma treated with autologous stem cell transplant (ASCT), "the presence of clonal hematopoiesis of indeterminate potential (CHIP) was associated with worse outcomes compared to those without CHIP. According to first study author Dr. Tarek H. Mouhieddine, the study results indicate that immunomodulatory therapy after transplant is a safe and viable option regardless of CHIP status.
To read more about the study, click here.
No comments:
Post a Comment